• Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed...
    3 KB (212 words) - 21:08, 11 November 2023
  • compound solution of sodium lactate (INN) Compro Comtan Comtrex Comvax conatumumab (USAN, INN) conbercept (INN) Concentraid Conceptrol Concerta concizumab...
    7 KB (431 words) - 01:43, 28 March 2025
  • Thumbnail for Tumor necrosis factor
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    49 KB (6,227 words) - 17:23, 29 April 2025
  • Thumbnail for List of therapeutic monoclonal antibodies
    humanized PTK7 cancer Coltuximab ravtansine mab chimeric CD19 cancer Conatumumab mab human TRAIL-R2 cancer Concizumab Alhemo mab humanized tissue factor...
    141 KB (4,321 words) - 00:07, 11 May 2025
  • Thumbnail for Tumor necrosis factor superfamily
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    8 KB (316 words) - 13:53, 10 September 2024
  • Thumbnail for Tumor necrosis factor receptor 2
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,387 words) - 13:47, 4 September 2024
  • proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    5 KB (305 words) - 05:22, 23 October 2024
  • Thumbnail for Lymphotoxin alpha
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    24 KB (2,769 words) - 05:48, 21 May 2025
  • Thumbnail for Tumor necrosis factor receptor 1
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    20 KB (2,146 words) - 16:24, 21 August 2024
  • Thumbnail for TNF receptor superfamily
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    9 KB (610 words) - 13:48, 14 January 2025
  • Thumbnail for Lymphotoxin beta
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,494 words) - 19:35, 4 September 2024
  • Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Cosibelimab Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab...
    5 KB (368 words) - 15:29, 21 August 2024
  • proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,464 words) - 17:22, 23 January 2025
  • Thumbnail for Lymphotoxin beta receptor
    proteins: Ardenermin Dulanermin Antibodies: Belimumab Brentuximab vedotin Conatumumab Dacetuzumab Denosumab Drozitumab Enavatuzumab Iratumumab Lexatumumab...
    12 KB (1,508 words) - 17:56, 19 August 2022
  • Thumbnail for Naptumomab estafenatox
    Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Cosibelimab Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab...
    4 KB (241 words) - 13:42, 14 July 2024
  • Atezolizumab (+hyaluronidase) Balstilimab† Botensilimab Cixutumumab§ Conatumumab§ Cosibelimab Daratumumab Drozitumab§ Duligotumab§ Dusigitumab§ Enfortumab...
    3 KB (129 words) - 01:04, 19 July 2023